Raffles Medical Group
Recommendation: Buy
Target price: S$1.15
Closing price: S$0.82 (−1.80%)
The group's margins are set to improve as its China operations move towards breaking even on an earnings before interest, tax, depreciation and amortisation (EBITDA) basis.
We forecast double-digit earnings growth for the group from FY2025 to FY2027, with overall healthcare revenue expected to exceed pre-pandemic levels.
In addition, the group's current valuation is attractive, trading below its regional peers. (RHB Securities)
For more information on the Singapore stock market, click here.